COVID-19 – Biofortis’ Continuity Plan

Biofortis, covid19

UPDATE – November 4th of 2020

The French President has announced a 30-day lockdown requiring the majority of residents to remain at home. Please know that our two Biofortis clinical centers (Paris and Nantes) will remain open during this time in accordance with the rules established for this lockdown. 

And, our team is currently working to identify solutions which allow us to reduce the number of in‐person visits to the clinic while also maintaining the integrity of your trial. Our priorities will be to protect the safety of study subjects as well as to ensure the scientific relevance and quality of each study.

The central lab will also remain open during this time to ensure ongoing specimen management, kit logistics and sample analysis.

Meanwhile, our Biofortis team is working diligently, remotely or on site, in order to guarantee the turnaround time of your project and to minimize the impact of this current crisis on your study activities.

Our entire Biofortis team remains at your disposal should you have any questions.

We sincerely hope that you and your family will not suffer from this virus and I am looking forward to seeing you soon.

In addition of our standard services (clinical trial, central lab, microbiome, data analytics) and according the roots of our company, Biofortis supports the french COVID-19 testing program with two new services in response to the current health challenges: 

  • in vitro Diagnostics / as part of the national effort to deploy diagnostic tests, Biofortis has received an agreement to perform the detection of the SARS-CoV-2 genome by RT PCR

  • SARS-CoV-2 Surface PCR testing / in support of MXNS laboratories by opening access to some of our facilities and equipment

Detection of the SARS-CoV-2 genome by RT PCR

We come in support of the medical laboratory to offer our services in order to respond to a public health issue. Indeed, as a central lab for clinical studies, we are used to working on germs, including some dangerous bacteria. Thus, we already have completely secure procedures and premises in place. This type of public health mission therefore makes sense for Biofortis. Today, before putting these analyses into practice, several validations have to be carried out (analytical and organisational in particular). To ensure the safety of our employees and volunteers, Biofortis will receive only samples in its laboratory to conduct the analytical part of the diagnosis: the 1st stage of nasopharyngeal sampling and the last stage of biological validation will be carried out by medical laboratories. 

Here is a link towards an article written by Thomas Carton one month ago, about the detection method of coronavirus if you want to know more: About Coronavirus detection methods

Don’t hesitate to contact us for more information:

covid19 biofortis


May 14/15/16th, 2024in Geneva, Swiss[EVENT] - Biofortis will be present at Vitafoods Europe 2024   For this 2024 edition, we will be present together with analyze & realize, one of the leading...

[EVENT] – Biofortis will be present at PHARMABIOTICS 2024 

March 12/13/14th, 2024in Lille, France For this 2024 edition, Biofortis will be present during the Pharmabiotic Research Institute (PRI)'s annual conference in LILLE, France, 12/13/14 March 2024.  ...

Perform a user experience study under expert control

What is a user experience study? As a clinical research expert, Biofortis can also conduct other types of studies, namely user experience studies. If you have a product to promote (functional...

Biofortis will be present at PROBIOTA 2024 – Supporter level sponsor

Feb. 7th to 9th, 2024in Milan, ITALYCome and meet us at PROBIOTA in Milan, Italy.Probiota 2024, the leading Microbiome and must attend industry event will take place in the design capital of the...

[EVENT] Biofortis will be present at FIE

Nov. 28th to 30th, 2023in Frankfurt, GERMANYCome and meet us at Food Ingredients Europe (FIE) in Frankfurt, Germany.Fi Europe is the world's largest gathering of F&B ingredient buyers and...

[PRESS RELEASE] Biofortis strengthens its service offerings with the acquisition of analyze & realize

We are excited to announce that Biofortis, a leading European premium CRO has completed the acquisition of analyze & realize GmbH.    Based in Berlin, with more than 20 years’ experience in...

[EVENT] Biofortis will be present at NUTREVENT – SILVER SPONSOR 

October 17th & 18th 2023in Rennes, FRANCECome and meet us at NutrEvent in Rennes, France.As the European leading partnering event, NutrEvent is dedicated to innovation in Food, Human and Animal...


In a continuous improvement of our performance and analytical capabilities that's complements Biofortis Central lab, our expert staff members have worked to implement a new machine: LUMINEX LX-200. ...

[EVENT] Biofortis will be present at Outsourcing In Clinical Trials Europe 2023

May 3rd and 4th, 2023in Barcelona, SpainCome and meet us at the Outsourcing In Clinical Trials (OCT) Europe 2023 in Barcelona; Spain.   This event will provide participants with practical take-away...

[EVENT] Biofortis will be present at Vitafoods Europe 2023

May 9th to 11th, 2023in Geneva, SwitzerlandFor this 2023 edition, Vitafoods Europe 2023 will take a hybrid format: we will be present both virtual and in person, in Geneva, Switzerland. Vitafoods...